Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Completion of THX-110 trial marks a step forward for medical cannabis development
  2. AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
  3. TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
  4. ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
  5. CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer

Latest Content

Completion of THX-110 trial marks a step forward for medical cannabis development

Therapix Biosciences, a biopharmaceutical company focused on the development of cannabinoid-based treatments, reported topline data on April 9th from a Phase IIa study at Yale University showing that its cannabinoid-based treatment, THX-110, met its primary endpoint for Tourette syndrome (TS). THX-110, which is a combination drug of dronabinol (THC) and palmitoylethanolamide (PEA), significantly improved symptoms in adult subjects with the disorder.

Gene-edited stem cells reduce HIV risk in non-human primates

Researchers have found that by genetically editing bone marrow stem cells of pigtail macaques infected with simian/human immunodeficiency virus (SHIV), the size of dormant ‘viral reservoirs’ can be reduced, decreasing the risk of the disease reactivating.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top